Danaher Co. (NYSE:DHR) Stock Holdings Boosted by Hengehold Capital Management LLC

Hengehold Capital Management LLC boosted its position in Danaher Co. (NYSE:DHR) by 11.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,796 shares of the conglomerate’s stock after buying an additional 180 shares during the quarter. Hengehold Capital Management LLC’s holdings in Danaher were worth $499,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. CWM LLC raised its stake in Danaher by 14.6% during the 1st quarter. CWM LLC now owns 21,912 shares of the conglomerate’s stock valued at $5,472,000 after acquiring an additional 2,799 shares in the last quarter. Ferguson Wellman Capital Management Inc. raised its stake in shares of Danaher by 9.1% during the first quarter. Ferguson Wellman Capital Management Inc. now owns 1,519 shares of the conglomerate’s stock valued at $379,000 after purchasing an additional 127 shares in the last quarter. Montecito Bank & Trust lifted its holdings in Danaher by 10.7% in the first quarter. Montecito Bank & Trust now owns 4,023 shares of the conglomerate’s stock worth $1,005,000 after purchasing an additional 388 shares during the period. Wedmont Private Capital grew its position in Danaher by 14.6% in the 1st quarter. Wedmont Private Capital now owns 4,391 shares of the conglomerate’s stock valued at $1,097,000 after buying an additional 561 shares in the last quarter. Finally, McLean Asset Management Corp acquired a new position in Danaher during the 1st quarter valued at about $207,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Up 3.2 %

NYSE:DHR opened at $276.50 on Thursday. The business’s fifty day moving average price is $270.53 and its 200 day moving average price is $259.65. The firm has a market capitalization of $204.80 billion, a price-to-earnings ratio of 45.42, a PEG ratio of 4.49 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period in the prior year, the firm earned $2.05 earnings per share. The firm’s revenue was down 2.9% compared to the same quarter last year. On average, sell-side analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Analyst Ratings Changes

DHR has been the subject of a number of research analyst reports. Wells Fargo & Company started coverage on shares of Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price target for the company. Stifel Nicolaus increased their price target on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Stephens started coverage on Danaher in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 price objective on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 target price on shares of Danaher in a research note on Friday, September 6th. Finally, TD Cowen boosted their price target on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $282.12.

Insider Transactions at Danaher

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at approximately $8,229,254.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is owned by insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.